Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immunocore Holdings Plc ADR (IMCR)

Immunocore Holdings Plc ADR (IMCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,615,065
  • Shares Outstanding, K 50,033
  • Annual Sales, $ 249,430 K
  • Annual Income, $ -55,290 K
  • EBIT $ -69 M
  • EBITDA $ -65 M
  • 60-Month Beta 0.72
  • Price/Sales 6.44
  • Price/Cash Flow N/A
  • Price/Book 4.25

Options Overview Details

View History
  • Implied Volatility 53.76% ( -0.95%)
  • Historical Volatility 40.72%
  • IV Percentile 39%
  • IV Rank 16.31%
  • IV High 109.35% on 05/22/24
  • IV Low 42.93% on 12/15/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 1,929
  • Open Int (30-Day) 2,068

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.41
  • Number of Estimates 7
  • High Estimate -0.09
  • Low Estimate -0.93
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -2.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.13 +7.15%
on 11/05/24
35.47 -8.99%
on 10/28/24
-1.03 (-3.09%)
since 10/22/24
3-Month
29.72 +8.61%
on 10/03/24
37.47 -13.85%
on 08/27/24
-3.32 (-9.33%)
since 08/22/24
52-Week
29.72 +8.61%
on 10/03/24
76.98 -58.07%
on 02/01/24
-13.39 (-29.32%)
since 11/22/23

Most Recent Stories

More News
Corcept Shares Rise More Than 60% in Three Months: Here's Why

Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline of 9.9%.The company’s sole-marketed drug, Korlym (mifepristone), which is...

CORT : 57.54 (+2.90%)
IMCR : 32.28 (+0.50%)
CSTL : 29.81 (+3.22%)
SPRO : 1.1600 (-2.52%)
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer

Puma Biotechnology, Inc. PBYI announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline candidate, alisertib, for the treatment of patients with metastatic breast cancer.The...

IMCR : 32.28 (+0.50%)
PBYI : 3.00 (+3.45%)
CSTL : 29.81 (+3.22%)
SPRO : 1.1600 (-2.52%)
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study

Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating cognitive impairment (CI) associated with Huntington’s Disease (HD) failed to...

IMCR : 32.28 (+0.50%)
CSTL : 29.81 (+3.22%)
SAGE : 5.17 (+6.60%)
SPRO : 1.1600 (-2.52%)
FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 32.28 (+0.50%)
CSTL : 29.81 (+3.22%)
FATE : 2.29 (+10.63%)
SPRO : 1.1600 (-2.52%)
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus

Fate Therapeutics FATE reported a loss of 40 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 42 cents. The company reported a loss of 46 cents per...

IMCR : 32.28 (+0.50%)
CSTL : 29.81 (+3.22%)
ANIP : 56.91 (+1.88%)
FATE : 2.29 (+10.63%)
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark

SpringWorks Therapeutics, Inc. SWTX incurred a loss of 72 cents per share in the third quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported...

IMCR : 32.28 (+0.50%)
CSTL : 29.81 (+3.22%)
ANIP : 56.91 (+1.88%)
SWTX : 39.02 (+7.49%)
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised

Mirum Pharmaceuticals, Inc. MIRM incurred a loss of 30 cents per share in third-quarter 2024, much narrower than the Zacks Consensus Estimate of a loss of 45 cents. The company had reported a loss of 57...

IMCR : 32.28 (+0.50%)
MIRM : 44.73 (+2.87%)
CSTL : 29.81 (+3.22%)
ANIP : 56.91 (+1.88%)
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus

Rocket Pharmaceuticals, Inc. RCKT incurred a loss of 71 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 78 cents. In the year-ago quarter, the company...

FOLD : 9.66 (+1.68%)
IMCR : 32.28 (+0.50%)
CSTL : 29.81 (+3.22%)
RCKT : 14.11 (+10.32%)
3 Fast-Growing Stocks Analysts See Doubling in Price

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.

IMCR : 32.28 (+0.50%)
GHRS : 9.27 (-3.64%)
NTLA : 14.30 (+3.62%)
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up

Puma Biotechnology, Inc. PBYI reported third-quarter 2024 adjusted earnings of 45 cents per share, which beat the Zacks Consensus Estimate of 35 cents. In the year-ago quarter, the company had reported...

FOLD : 9.66 (+1.68%)
IMCR : 32.28 (+0.50%)
PBYI : 3.00 (+3.45%)
CSTL : 29.81 (+3.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 34.13
2nd Resistance Point 33.69
1st Resistance Point 32.98
Last Price 32.28
1st Support Level 31.83
2nd Support Level 31.39
3rd Support Level 30.68

See More

52-Week High 76.98
Fibonacci 61.8% 58.93
Fibonacci 50% 53.35
Fibonacci 38.2% 47.77
Last Price 32.28
52-Week Low 29.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar